Seminars in Oncology
Volume 30, Issue 2 , Pages 110-115 , April 2003

Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

References 

  1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia—A new syndrome?. Acta Med Scand. 1944;117:216–247
  2. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al.  Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol. 2000;18:214–226
  3. Owen RG, Johnson SA, Morgan GJ. Waldenström's macroglobulinaemia: Laboratory diagnosis and treatment. Hematol Oncol. 2000;18:41–49
  4. Nakata M, Matsuno Y, Takenaka T, et al.  B-cell lymphoma accompanying monoclonal macroglobulinemia with features suggesting marginal zone B-cell lymphoma. Int J Hematol. 1997;65:405–411
  5. Allez M, Mariette X, Linares G, et al.  Low-grade MALT lymphoma mimicking Waldenström's macroglobulinemia. Leukemia. 1999;13:484–485
  6. Valdez R, Finn WG, Ross CW, et al.  Waldenström macroglobulinemia caused by extranodal marginal zone B-cell lymphoma. Am J Clin Pathol. 2001;116:683–690
  7. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  8. Jaffe ES, Harris NL, Stein H, et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: , IARC Press; 2001;
  9. Owen RG, Parapia LA, Richards SJ, et al.  Paraprotein status in lymphoplasmacytoid lymphoma/immunocytoma: Do all cases correspond to Waldenström's macroglobulinaemia?. Br J Haematol. 1999;105(suppl 1):89; abstr)
  10. Papamichael D, Norton AJ, Foran JM, et al.  Immunocytoma: A retrospective analysis from St Bartholomew's Hospital—1972 to 1996. J Clin Oncol. 1999;17:2847–2853
  11. Sahota S, Garand R, Bataille R, et al.  VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. Blood. 1998;91:236–243
  12. Moore DF, Migliore PJ, Shullenberger CC, et al.  Monoclonal macroglobulinemia in malignant lymphoma. Ann Intern Med. 1970;72:43–47
  13. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc. 1987;62:719–731
  14. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am. 1999;13:1181–1201
  15. Owen RG, Parapia LA, Higginson J, et al.  Clinicopathological correlates of IgM paraproteinemias. Clin Lymph. 2000;l:39–43
  16. Facon T, Brouillard M, Duhamel A, et al.  Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases. J Clin Oncol. 1993;11:1553–1558
  17. Gobbi PG, Bettini R, Montecucco C, et al.  Study of prognosis in Waldenström's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939–2945
  18. Morel P, Monconduit M, Jacomy D, et al.  Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852–858
  19. Owen RG, Barrans SL, Richards SJ, et al.  Waldenström macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420–428
  20. Garcia-Sanz R, Montoto S, Torrequebrada A, et al.  Waldenström macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575–582
  21. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al.  Waldenström's macroglobulinemia: Clinical course and prognostic features in 60 patients. Ann Hematol. 2001;80:722–727
  22. Bartl R, Frisch B, Mahl G, et al.  Bone marrow histology in Waldenström's macroglobulinaemia. Scand J Haematol. 1983;3:359–375
  23. Andriko JW, Aguilera NS, Chu WS, et al.  Waldenström's macroglobulinemia. A clinicopathologic study of 22 cases. Cancer. 1997;80:1926–1935
  24. Feiner HD, Rizk CC, Finfer MD, et al.  IgM monoclonal gammopathy/Waldenström's macroglobulinemia: A morphological and immunophenotypic study of the bone marrow. Mod Pathol. 1990;3:348–356
  25. Matutes E, Owusu-Ankomah K, Morilla R, et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645
  26. Kelliher A, Preffer F, Frankel SR, et al.  Expression of serotherapy target antigens in lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia). Proc Am Soc Clin Oncol. 2002;21:279a; (abstr)
  27. San Miguel JF, Vidriales MB, Mateo G, et al.  Immunophenotypic analysis of Waldenström's macroglobulinemia. Semin Oncol. 2003;30:187–195
  28. Leitch D, O'Connor SJM, Barrans SL, et al.  Waldenstrom's macroglobulinemia is characterised by a memory B-cell immunophenotype and the absence of immunoglobulin translocations. Blood. 2002;100(suppl 1):347a; abstr)
  29. Zarrabi MH, Stark RS, Kane P, et al.  IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia. Am J Clin Pathol. 1981;75:1–10
  30. Takahashi K, Yamamura F, Motoyama H. IgM myeloma—Its distinction from Waldenström's macroglobulinemia. Acta Pathol Jpn. 1986;36:1553–1563
  31. Haghighi B, Yanagihara R, Cornbleet PJ. IgM myeloma: Case report with immunophenotypic profile. Am J Clin Pathol. 1998;59:302–308
  32. Konda H, Yokoyama K. IgM myeloma: Different features from multiple myeloma and macroglobulinaemia. Eur J Haematol. 1999;63:366–368
  33. Dierlamm T, Laack E, Dierlamm J, et al.  IgM myeloma: A report of four cases. Ann Hematol. 2002;81:136–139
  34. Avet-Loiseau H, Garand R, Lode L, et al.  14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:153–155
  35. Palka G, Spadano A, Geraci L, et al.  Chromosome changes in 19 patients with Waldenström's macroglobulinemia. Cancer Genet Cytogenet. 1987;29:261–269
  36. Louviaux I, Michaux L, Hagemeijer A, et al.  Cytogenetic abnormalities in Waldenstöm's disease (WD): A single center study on 45 cases. Blood. 1998;92(suppl 1):3776; abstr)
  37. Carbone P, Caradonna F, Granata G, et al.  Chromosomal abnormalities in Waldenström's macroglobulinemia. Cancer Genet Cytogenet. 1992;61:147–151
  38. Mansoor A, Medeiros J, Weber DM, et al.  Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543–549
  39. Schop RFJ, Kuehl WM, Van Wier SA, et al.  Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions. Blood. 2002;100:2996–3001
  40. Offit K, Parsa NZ, Filippa D, et al.  t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 1992;80:2594–2599
  41. Iida S, Rao PH, Nallasivam P, et al.  The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996;88:4110–4117

☆ Address reprint requests to Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute, Harvard Medical School, LG100, 44 Binney St, Boston, MA 02115. Email: wmp@dfci.harvard.edu.

☆☆ 0093-7754/03/3002-0002$30.00/0

PII: S0093-7754(03)70059-1

doi: 10.1053/sonc.2003.50082

Seminars in Oncology
Volume 30, Issue 2 , Pages 110-115 , April 2003

Article Tools